|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
gptkb:opioid
|
|
gptkbp:actsOn
|
gptkb:opioid
gptkb:opioid_receptor_agonist
|
|
gptkbp:ATCCode
|
V03AB05
|
|
gptkbp:CASNumber
|
62-67-9
|
|
gptkbp:category
|
phenols
allyl compounds
kappa-opioid receptor agonists
morphinans
mu-opioid receptor antagonists
semisynthetic opioids
|
|
gptkbp:derivedFrom
|
gptkb:morphine
|
|
gptkbp:developedBy
|
1950s
|
|
gptkbp:discoveredBy
|
gptkb:Everett_L._May
|
|
gptkbp:hasInChIKey
|
QIDNNJFMUCGCJL-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C19H21NO3
|
|
gptkbp:hasSMILES
|
C=CCN1CC[C@]23c4c5ccc(O)cc4O[C@H]2C=C[C@@H]3[C@H]1C5
|
|
gptkbp:isomerOf
|
gptkb:morphine
|
|
gptkbp:IUPACName
|
(5α,6β)-17-allyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
|
|
gptkbp:legalStatus
|
withdrawn in many countries
|
|
gptkbp:meltingPoint
|
230–232 °C
|
|
gptkbp:molecularWeight
|
311.38 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
4417
DB01450
|
|
gptkbp:replacedBy
|
gptkb:naloxone
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
respiratory depression
hallucinations
dysphoria
|
|
gptkbp:synonym
|
N-allylnormorphine
Nalline
|
|
gptkbp:UNII
|
6YKS4Y3WQ7
|
|
gptkbp:usedAs
|
antidote to opioid overdose
diagnostic agent for opioid dependence
|
|
gptkbp:bfsParent
|
gptkb:Schedule_III_controlled_substances
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nalorphine
|